Mankind Pharma
Tracked across 5 events · 33 articles · First seen Mar 20, 2025 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., a China-based biopharmaceutical company, to commercialize two insulin analogues in India: Insulin Degludec and a combination of Insulin…
Impact: Mankind Pharma is the licensee and will commercialize the insulin analogues in India, strengthening its diabetes portfolio and injectable segment. The deal is expected to enhance its market position and revenue potential.
Aug 20, 2026 · 6 articles
Regulatory
Impact: Arjun Juneja, COO of Mankind Pharma, highlighted India's strong pharmaceutical base and the need for collaboration.
Apr 12, 2026 · 6 articles
Business
Impact: Mankind Pharma is an Indian generic drugmaker preparing to enter the market with generic versions of semaglutide.
Nov 11, 2025 · 6 articles
Business
Impact: Mankind Pharma is a marquee customer of Sudeep Pharma, highlighting its strong client relationships.
Nov 19, 2025 · 8 articles
Business
Impact: Mankind Pharma is an existing investor; its stake may be affected by valuation changes.
Jul 30, 2026 · 7 articles
100
Mankind Pharma signed exclusive licensing deal Chongqing Chenan BiopharmaceuticalMankind Pharma licenses...
ERGEN INTELLIGENCE
Track Mankind Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard